Detection of desmoglein-2 in cancers of epithelial origin
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Htd Bio Corp • WASHINGTON, University of • HDT Bio Corp
Member
HDT BioHDT Bio is a clinical-stage biopharmaceutical company based in Seattle, developing novel technologies and products designed to harness and enhance the immune system for the treatment and prevention of cancer and infectious diseases. HDT Bio utilizes advanced immunotherapeutic platforms, including a proprietary nanoparticle delivery system, to provide safe, potent, and durable solutions that enable rapid clinical translation and personalized cancer therapies. The company's multidisciplinary team and international partnerships facilitate robust clinical development, innovative product design, and global distribution with the goal of improving patient outcomes worldwide.
HDT Bio is a clinical-stage biopharmaceutical company based in Seattle, developing novel technologies and products designed to harness and enhance the immune system for the treatment and prevention of cancer and infectious diseases. HDT Bio utilizes advanced immunotherapeutic platforms, including a proprietary nanoparticle delivery system, to provide safe, potent, and durable solutions that enable rapid clinical translation and personalized cancer therapies. The company's multidisciplinary team and international partnerships facilitate robust clinical development, innovative product design, and global distribution with the goal of improving patient outcomes worldwide.
Publication Number
US-12669505-B2
Publication Date
2026-06-30
Expiration Date
Abstract
The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.
Core Innovation
The disclosed invention relates to detecting desmoglein-2 (DSG-2) expression in ovarian cancer and using DSG-2 expression to diagnose chemo-resistance. The approach compares DSG-2 expression in an ovarian cancer sample obtained from the subject prior to treatment with the DSG-2 expression in the same type of sample following treatment with one or more chemotherapeutic agents. A higher amount of DSG-2 expression following treatment relative to prior to treatment indicates that the ovarian cancer is chemo-resistant.
The invention further provides that a subject diagnosed with chemo-resistant ovarian cancer is treated by administering an effective amount of a DSG-2 binding reagent. The DSG-2 binding reagent comprises a junction opener. DSG-2 detection is described through binding reagents such as antibodies, aptamers, engineered proteins, or molecularly imprinted matrices to measure DSG-2.
In the disclosed systems and analyses, DSG-2 expression in cancers of epithelial origin is discussed with particular emphasis on ovarian cancer. The partial content describes DSG-2 elevation, including after chemotherapy such as cisplatin, in chemo-resistant settings compared with chemosensitive controls. The document links these observations to survival outcomes including progression-free survival and overall survival, as well as to treatment stratification.
Claims Coverage
The independent claim covers a treatment-and-diagnosis workflow for chemo-resistant ovarian cancer based on detecting DSG-2 expression before and after treatment with one or more chemotherapeutic agents, followed by administering a DSG-2 binding reagent that comprises a junction opener together with the chemotherapeutic agents. The claim includes inventive features spanning sample acquisition, DSG-2 expression detection as a chemo-resistance diagnostic, and combination treatment with a junction-opener DSG-2 binding reagent.
Detecting DSG-2 expression to diagnose chemo-resistance
Obtaining an ovarian cancer sample from the subject; detecting desmoglein-2 (DSG-2) expression in the ovarian cancer sample; diagnosing the chemo-resistant ovarian cancer wherein a higher amount of DSG-2 expression in the ovarian cancer sample following treatment with one or more chemotherapeutic agents relative to DSG-2 expression prior to the treatment indicates that the ovarian cancer is chemo-resistant.
Administering an effective amount of a junction-opener DSG-2 binding reagent with chemotherapy
Administering to the subject an effective amount of a DSG-2 binding reagent, wherein the DSG-2 binding reagent comprises a junction opener; and administering the one or more chemotherapeutic agents.
Across the independent claim, the inventive coverage is centered on using post-treatment increases in DSG-2 expression relative to pre-treatment levels to diagnose chemo-resistant ovarian cancer, and then administering an effective amount of a DSG-2 binding reagent that comprises a junction opener in combination with the one or more chemotherapeutic agents.
Stated Advantages
Enables diagnosis of chemo-resistant ovarian cancer by indicating chemo-resistance when DSG-2 expression increases following treatment relative to expression prior to treatment.
Supports treatment of a subject suffering from chemo-resistant ovarian cancer by administering a junction-opener DSG-2 binding reagent together with one or more chemotherapeutic agents.
Documented Applications
Use of DSG-2 expression detection to diagnose chemo-resistance and guide treatment stratification in chemo-resistant ovarian cancer.
Association of elevated DSG-2 expression, including after chemotherapy such as cisplatin, with chemotherapy refractoriness and survival outcomes such as progression-free survival and overall survival.
Assessment of DSG-2 expression using DSG-2 binding reagents and related assay modalities described in the partial content, including immunohistochemistry, quantitative ELISA, Western blot, and mRNA assays (qPCR/RNA-seq).
Interested in licensing this patent?